78 FR 245 pg. 77107 - Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Antibody-Dependent Cellular Cytoxicity (ADCC)-Mediating Antibodies
Type: NOTICEVolume: 78Number: 245Page: 77107
Page: 77107FR document: [FR Doc. 2013-30367 Filed 12-19-13; 8:45 am]
Agency: Defense Department
Sub Agency: Army Department
Official PDF Version: PDF Version
[top]
DEPARTMENT OF DEFENSE
Department of the Army
Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Antibody-Dependent Cellular Cytoxicity (ADCC)-Mediating Antibodies
AGENCY:
Department of the Army, DoD.
ACTION:
Notice.
SUMMARY:
Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/762,543, entitled "Antibody-Dependent Cellular Cytoxicity (ADCC)-Mediating Antibodies," filed on February 8, 2013. The United States Government, as represented by the Secretary of the Army, has rights to this invention.
ADDRESSES:
Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.
FOR FURTHER INFORMATION CONTACT:
For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619-6664, both at telefax (301) 619-5034.
SUPPLEMENTARY INFORMATION:
The invention relates to Antibody-Dependent cellular cytoxicity (ADCC)-mediating antibodies, and, in particular, to ADCC-mediating antibodies (and fragments thereof) suitable for use, for example, in reducing the risk of HIV-1 infection in a subject. The invention further relates to compositions comprising such antibodies or antibody fragments.
Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 2013-30367 Filed 12-19-13; 8:45 am]
BILLING CODE 3710-08-P